All News
We've got another resource available on Cytokine Storm Management. Log in and download today.
https://t.co/dTAzMVa6SB https://t.co/BvsZFxGrQl
Links:
Dr. John Cush RheumNow ( View Tweet)
The current NEJM reports that the use of the Pfizer mRNA vaccine (BNT162b2) demonstrated a very low risk for certain serious adverse events, including the risk of myocarditis (1 to 5 events per 100,000 persons).
https://t.co/CT4dQK9XlH https://t.co/enddiHtX1G
Links:
Dr. John Cush RheumNow ( View Tweet)
1458 RA patients (74% seropositive) followed longitudinally for ROM & surgical outcomes. Seropositive and seronegative patients had loss of ROM over time (7–13%/Yr), and surgical needs. T2T approaches should be followed irrespective of RF status https://t.co/ohmDTLfP9S
Links:
Dr. John Cush RheumNow ( View Tweet)
85% relapse median 22 wks , 20% ISR, quickly regain MDA, why would you? https://t.co/VtQ3ClumBl
Peter Nash drpnash ( View Tweet)
Can an anti-inflammatory diet impact axial spondyloarthritis (axSpA)? A 6-month dietary intervention shows that adherence to a Mediterranean diet lowers disease activity in axSpA; but dietary adherence is often incomplete.
https://t.co/AqtYO60XbH https://t.co/uYil2YvOR1
Links:
Dr. John Cush RheumNow ( View Tweet)
A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive RA.
https://t.co/szl5L7DGJG https://t.co/vAXBNPxsWU
Links:
Dr. John Cush RheumNow ( View Tweet)
Arthritis clinic referrals divided into 2 cohorts: (A) 163 w/ MSK US before visit; (B) 109 without initial MSK US. MSK-US at 1st visit reduced time to Dx from mean 31 to 12 days (p< 0.01), # of clinic visits, & increased odds of inflamm Dx (47% vs 27%) https://t.co/FaXLBlRlxy
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters
https://t.co/vT6185ycoG https://t.co/G14eLN2JkT
Links:
Dr. John Cush RheumNow ( View Tweet)
Si @DGlaucomflecken es el mejor se dice y ya está https://t.co/QzPyIe5gAA
Raruniente Raruniiente ( View Tweet)
New podcast available for download!
COVID Marching Amidst the Madness
https://t.co/xYzkw3zGRt https://t.co/gv45nVk9v5
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it:
Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis
Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).
https://t.co/2YbLBsFedv https://t.co/OYMJ6Y54UF
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa
Links:
Dr. John Cush RheumNow ( View Tweet)
Oligoarticular vs. Polyarticular Psoriatic Arthritis
https://t.co/lQVNdmWgMc https://t.co/ZjyDeYTLe2
Links:
Dr. John Cush RheumNow ( View Tweet)
We've got a new podcast up for you, focusing on all of this week's top stories on RheumNow.
https://t.co/xYzkw3zGRt https://t.co/A75Cl3WYno
Links:
Dr. John Cush RheumNow ( View Tweet)
Cochrane review finds only 2 studies showing tocilizumab to be beneficial in GCA (sustained remission, relapse-free survival, need for escape therapy). https://t.co/sQjIBAiWKN
Links:
Dr. John Cush RheumNow ( View Tweet)
Swedish study of 287 SLE pts shows rare risk of autoimmune liver disease. While 14% had persistent LFTs, only 2.8% dx w/ autoimmune hepatitis. 1.4-2.1% met criteria for primary biliary cholangitis. Both AIH & PBC AIH are overrepresented in SLE https://t.co/oc5SLJtycf
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 36 studies, 608 RA-Bronchiectasis among 8569 RA pts; pooled bronchiectasis prevalence in RA was 18.7% (range 15.5% to 20.7%). Risk factors: older age, longer RA duration, genetics (CFTR & HLA), undetectable MBL biomarker https://t.co/SSRoTCYkHf
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs
https://t.co/XO4DPXwGQi https://t.co/S9E3yENfDF
Links:
Dr. John Cush RheumNow ( View Tweet)
Brazilian national study of 319 SLE & 251,800 nonSLE pts hospitalized with COVID-19 showed that SLE increases risk of death (RR 1.74) & poor outcomeS (RR 1.39). Having lupus doubled (RR 2.2) the risk of risk of death. https://t.co/8VJjdOEuzS
Links:
Dr. John Cush RheumNow ( View Tweet)